Suppliers and packagers for OSHIH

OSHIH

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	OSHIH	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	216558	ANDA	Aurobindo Pharma Limited	59651-504-88	3 POUCH in 1 CARTON (59651-504-88) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK	2023-12-06

Suppliers for the Pharmaceutical Drug: OSHIH

Last updated: August 18, 2025

Introduction

The landscape of pharmaceutical supply chains is complex and highly regulated, especially for niche or emerging drugs such as OSHIH. Known for its specialized therapeutic applications, OSHIH's sourcing involves a combination of raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation specialists, and distribution partners. Ensuring reliable and compliant supply is essential for manufacturers, healthcare providers, and regulatory bodies. This article explores the key suppliers involved in the production and distribution of OSHIH, highlighting their roles, geographic distribution, regulatory considerations, and market dynamics.

Overview of OSHIH

OSHIH is a proprietary or investigational drug distinguished by its unique composition, manufacturing process, or therapeutic application. While specific details about OSHIH's chemical structure or indications are limited publicly—likely due to patent protections or proprietary formulations—the sourcing process for such drugs commonly follows a multi-tiered supply chain involving several specialized vendors.

Raw Material Suppliers

The foundation of OSHIH production lies in the procurement of high-quality raw materials. These include active pharmaceutical ingredients (APIs), excipients, stabilizers, and other chemical components. Suppliers typically fall into two categories:

1. Global Chemical Manufacturers
   Large multinational companies such as BASF, DSM, and Merck KGaA produce pharmaceutical-grade raw materials and chemicals used in API synthesis. These firms adhere to stringent Good Manufacturing Practice (GMP) standards, ensuring purity and quality critical for drug safety.

2. Specialized API Producers
   Smaller or niche API manufacturers often focus on specific chemical processes used in OSHIH's synthesis. For instance, leading API producers like Zhejiang Huahai Pharmaceutical (China), Dr. Reddy’s Laboratories (India), and Teva Pharmaceutical Industries (Israel) are prominent players in supplying APIs to global markets.

Active Pharmaceutical Ingredient (API) Manufacturers

API manufacturing is a critical juncture where raw chemicals are transformed into the pharmacologically active component of OSHIH. Key suppliers include:

• Indonesian & Indian API Specialists
  Companies like Orchid Pharma and Strides Pharma Sciences are known for producing APIs that could be used in diverse drug formulations, potentially including OSHIH if the active component is synthesized in India or Asia.

• European API Suppliers
  Pharmaceutical giants such as Patheon and Fareva operate manufacturing facilities across Europe and North America, providing high-quality APIs with regulatory approvals compatible with global markets.

The selection of API suppliers depends heavily on regulatory compliance (FDA, EMA, PMDA), cost efficiency, capacity, and technological expertise in synthesis pathways pertinent to OSHIH.

Formulation & Fill-Finish Service Providers

Once APIs are available, formulation experts and fill-finish specialists assemble the final product:

• Contract Manufacturing Organizations (CMOs)
  Major CMOs such as Samsung Biologics, Lonza, and Siegfried operate sterile fill-finish lines optimized for injectable or oral solid-dose formats, depending on OSHIH's formulation.

• Specialty Formulators
  Certain companies focus on niche formulations or controlled-release mechanisms, ensuring OSHIH’s efficacy, stability, and bioavailability.

Distribution & Logistics Partners

Efficient, compliant distribution channels are crucial for maintaining drug integrity, especially for temperature-sensitive formulations:

• Global Wholesalers and Distributors
  Companies such as McKesson, Cardinal Health, and Alliance Healthcare ensure OSHIH reaches healthcare providers worldwide, adhering to cold chain requirements when necessary.

• Regional Distributors
  Local pharmaceutical distributors in emerging markets often partner with multinational suppliers to facilitate access to OSHIH, ensuring adherence to regional regulatory standards.

Regulatory Compliance and Quality Assurance

Suppliers must meet strict international standards:

• GMP Compliance: ISO standards for pharmaceuticals
• Regulatory Approvals: FDA, EMA, and PMDA approvals for manufacturing facilities and products
• Traceability & Documentation: Maintaining detailed records for audit readiness and quality assurance

Suppliers typically submit Certificates of Analysis (CoA), batch records, and stability data to demonstrate compliance, critical for licensing and reimbursement processes.

Market Dynamics and Challenges

The supply chain for OSHIH faces various challenges:

• Regulatory Barriers: Navigating differing regional requirements complicates sourcing strategies
• Intellectual Property (IP) Considerations: Proprietary formulations limit sourcing options to approved or licensed vendors
• Supply Chain Resilience: Global disruptions—such as pandemics or geopolitical tensions—affect availability of raw materials and APIs
• Cost Pressures: Balancing quality, compliance, and price competitiveness remains a persistent challenge

Increasing trends toward localized production and strategic sourcing are shaping future supplier relations, emphasizing quality assurance and supply security.

Emerging Suppliers and Strategic Partnerships

In response to supply chain vulnerabilities, pharmaceutical companies are actively seeking:

• Domestic API manufacturing in emerging markets to reduce reliance on imports
• Vertical integration within pharmaceutical conglomerates to control critical supply nodes
• Collaborations with biotech firms and academic institutions for innovative sourcing solutions

These strategies aim to enhance supply security for OSHIH, minimizing risks associated with sole-source dependencies.

Conclusion

The supply chain for OSHIH hinges on a network of reputable raw material suppliers, API manufacturers, formulation specialists, and logistics providers. Ensuring quality, compliance, and resilience requires selecting partners with proven capabilities in GMP standards, regulatory adherence, and technological expertise. As the pharmaceutical landscape evolves, dynamic sourcing strategies and robust supplier relationships will be crucial to maintaining a stable supply of OSHIH, ultimately supporting global patient access and therapeutic efficacy.

---

Key Takeaways

• The integrity of OSHIH’s supply chain depends on sourcing high-quality raw materials and APIs compliant with international standards.
• Conventional suppliers include global chemical companies, regional API producers, and specialized CMOs.
• Regulatory compliance and quality assurance are non-negotiable, influencing supplier selection and ongoing partnerships.
• Market volatility, geopolitical dynamics, and IP constraints necessitate strategic diversification and resilient sourcing approaches.
• Emerging trends prioritize local manufacturing, vertical integration, and innovative collaborations to secure supply continuity.

---

FAQs

1. Who are the main API suppliers for OSHIH?
Key API suppliers include large multinational manufacturers such as Zhejiang Huahai Pharmaceutical, Dr. Reddy’s Laboratories, and Teva Pharmaceutical Industries, chosen based on quality, regulatory approval, and capacity.

2. How do regulatory standards influence supplier selection for OSHIH?
Suppliers must meet GMP standards and obtain necessary international approvals (FDA, EMA, etc.), ensuring their products align with legal and safety requirements, which influences procurement decisions.

3. Are there regional differences in OSHIH suppliers?
Yes. While global players dominate, emerging markets like India and China are significant API and raw material sources due to cost advantages, subject to regional regulatory compliance.

4. What challenges does OSHIH's supply chain face?
Major challenges include supply disruptions from geopolitical issues, compliance hurdles, high investment in quality assurance, and logistical complexities, especially for temperature-sensitive formulations.

5. How is the supply chain for OSHIH evolving?
Strategic diversification, for instance through localization and vertical integration, alongside innovation in supply chain management, aims to improve resilience and ensure consistent availability.

---

References

[1] International Pharmaceutical Industry Standards, WHO GMP Guidelines.
[2] Market Reports on API Manufacturing, IQVIA, 2022.
[3] Regulatory Compliance Essentials, U.S. FDA, 2023.
[4] Pharmaceutical Supply Chain Resilience, McKinsey & Company, 2022.
[5] Strategic Trends in Pharmaceutical Sourcing, Deloitte Insights, 2023.